Identification of a Titin-Derived HLA-A1–Presented Peptide as a Cross-Reactive Target for Engineered MAGE A3–Directed T Cells

Brian Cameron1, Andrew B. Gerry2, Joseph Dukes1, Jane Harper1, Vivekanandan Kannan1, Frayne Bianchi1, Francis Grand1, Joanna E. Brewer2, Minnal Gupta3, Gabriela Plesa3, Giovanna Bossi1, Annelise Vuidepot1, Alex S. Powlesland1, Alison Legg1, Katherine J. Adams2, Alan Bennett2, Nicholas J. Pumphrey2, Daniel Williams2, Gwendolyn Binder-Scholl2, Irina Kulikovskaya3, Bruce L. Levine3, James L. Riley4, Angel Varela‐Rohena4, Edward A. Stadtmauer3, Aaron P. Rapoport5, Gerald P. Linette6, Carl H. June3, Namir J. Hassan1, Michael Kalos3, Bent K. Jakobsen2,1
1Immunocore Ltd., 57c Milton Park, Jubilee Avenue, Abingdon, OX14 4RX, UK.
2Adaptimmune Ltd., 57c Milton Park, Jubilee Avenue, Abingdon, OX14 4RX, UK.
3Abramson Cancer Center and Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
4Abramson Cancer Center and Department of Microbiology, University of Pennsylvania, Philadelphia, PA 19104, USA.
5The Greenebaum Cancer Center, University of Maryland, Baltimore, MD 21201, USA.
6Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO 63110, USA

Tóm tắt

T cells engineered to express affinity-enhanced TCRs directed to a MAGE A3 peptide cross-react with a similar, but unrelated, self-peptide.

Từ khóa


Tài liệu tham khảo

10.1038/nri3191

10.1038/mt.2010.24

10.1038/mt.2010.272

10.1200/JCO.2010.32.2537

Kalos M., Rapoport A. P., Stadtmauer E. A., Vogl D. T., Weiss B. M., Binder-Scholl G. K., Smethurst D. P., Kulikovskaya I., Gupta M., Macatee T. L., Finklestein J. M., Brewer J. E., Bennett A. D., Gerry A. B., Pumphrey N. J., Tayton-Martin H. K., Veloso E., Zheng Z., Badros A. Z., Yanovich S., Akpek G., McConville H., Philip S., Levine B. L., Jakobsen B. K., June C. H., Prolonged T cell persistence, homing to marrow and selective targeting of antigen positive tumor in multiple myeloma patients following adoptive transfer of T cells genetically engineered to express an affinity-enhanced T cell receptor against the cancer testis antigens NY-ESO-1 and Lage-1. Blood (ASH Annu. Meet. Abstr.) 120, 755 (2012).

10.1002/eji.201242606

10.1084/jem.189.3.461

10.1016/S1074-7613(00)80547-6

10.4049/jimmunol.180.9.6116

10.1038/ni863

10.1073/pnas.0507554102

10.1038/nbt1070

10.1016/j.jim.2008.09.016

10.1007/s12026-008-8057-6

10.1073/pnas.1005802107

10.1182/blood-2011-01-325266

10.1182/blood-2009-03-211714

10.1111/j.1349-7006.2009.01303.x

10.1084/jem.179.3.921

10.1002/ijc.2910630313

10.1002/ijc.2910640112

10.1126/science.1840703

10.4049/jimmunol.171.9.4898

10.1002/(SICI)1097-0215(19990118)80:2<219::AID-IJC10>3.0.CO;2-S

10.1084/jem.20031677

10.1158/0008-5472.CAN-07-5898

10.1182/blood-2013-03-490565

10.1152/ajpheart.00694.2011

10.1097/CJI.0b013e3182829903

10.1038/nm.2128

10.1038/mt.2010.195

10.1074/jbc.M111.289488

10.1007/BF00140321

10.1073/pnas.0813101106

10.1290/0512084.1

10.4049/jimmunol.171.1.166

10.1128/JVI.72.11.8463-8471.1998

10.1093/protein/gzg087

10.1073/pnas.89.8.3429

10.1006/abio.1998.2930

10.1038/nm.2764

10.1007/s00262-012-1384-4

10.1093/nar/25.17.3389

10.1097/00002371-199308000-00003

10.1093/nar/29.9.e45

10.1093/humrep/dem222